Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Overview of Oncocyte Corporation
Oncocyte Corporation (OCX) is a diagnostics technology company specializing in the discovery, development, and commercialization of advanced non-invasive diagnostic tests. Utilizing liquid biopsy techniques, Oncocyte is dedicated to improving clinical decision-making by enabling early and precise detection of cancer as well as monitoring transplant health. The company's innovative approach is built on proprietary biomarkers that allow differentiation between benign and malignant conditions, offering a disruptive solution in areas where conventional diagnostic methods are often ambiguous, invasive, or costly.
Core Business Areas and Technologies
At the heart of Oncocyte's business is its commitment to advancing molecular diagnostics through:
- Liquid Biopsy Diagnostics: Employing blood or urine samples, these non-invasive tests are designed to detect cancers such as lung, breast, and bladder by analyzing genetic markers and gene expression profiles.
- Transplant Monitoring: The company has developed sophisticated assays for monitoring organ transplant patients. For instance, VitaGraft Kidney leverages donor-derived cell-free DNA (dd-cfDNA) to detect early signs of graft injury or rejection, thereby providing actionable clinical insights.
- Advanced Molecular and Genetic Assays: Oncocyte's pipeline includes tests such as GraftAssure for research purposes and DetermaIO and DetermaCNI which assess the tumor microenvironment and copy number instability respectively, supporting therapeutic decision-making in oncology.
Scientific Approach and Industry Position
Oncocyte integrates state-of-the-art digital PCR technology and gene expression analysis to ensure high sensitivity, rapid turnaround times, and user-friendly workflows. This scientific rigor has established dd-cfDNA as a trusted biomarker in both oncology and transplant medicine. By addressing significant unmet clinical needs, such as reducing the time to diagnose antibody-mediated rejection in kidney transplants, Oncocyte positions itself as a key technology innovator within the broader molecular diagnostics industry.
Market Significance and Strategic Collaborations
The company has successfully carved out a niche in a competitive landscape by focusing its efforts on areas where diagnostic ambiguities and the invasiveness of current testing methods impact patient care. Its strategic partnerships with high-caliber industry players, including collaborations with research centers and established diagnostic firms, bolster its market presence. This collaborative strategy not only validates Oncocyte’s technology but also facilitates the land-and-expand approach needed to build a robust network of clinical adoption.
Operational Excellence and User-Centric Solutions
Oncocyte’s diagnostic tests are developed with an emphasis on scalability, cost-effectiveness, and ease of integration into existing clinical workflows. By delivering fast, reliable, and non-invasive testing options, the company helps physicians and health care providers make more informed decisions. This operational excellence reinforces the company’s reputation for combining innovative science with practical clinical utility, ensuring that both research and patient outcomes benefit from its technologies.
Research, Development, and Clinical Applications
Underpinned by over a decade of dedicated research into molecular biomarkers, Oncocyte continuously refines its product offerings to meet evolving clinical needs. The company’s broad R&D pipeline not only spans the detection and monitoring of cancer but also encompasses organ transplant applications that support early intervention. Its scientifically sound approach is corroborated by peer-reviewed publications and clinical studies, underscoring the potential of its assays to revolutionize diagnostic practices.
Conclusion
Oncocyte Corporation exemplifies the convergence of pioneering science, advanced diagnostic technology, and strategic market positioning in the field of molecular diagnostics. By offering breakthrough solutions that emphasize non-invasive testing and rapid clinical insights, the company stands as a robust resource for physicians, researchers, and healthcare providers. Its commitment to quality, scientific integrity, and practical application assures stakeholders of its capability to deliver reliable diagnostic outcomes across both oncology and transplant medicine.
Oncocyte (OCX) reports progress in commercializing its transplant rejection testing technology. The company has signed agreements with leading transplant centers in the U.S., Germany, Switzerland, Austria, and the U.K. Their customers now represent about 9% of German transplant volumes and 2% of U.S. transplant volumes. The company is on track to sign 20 transplant centers by end of 2025, with each center potentially generating annual revenue of several hundred thousand to $2 million. The FDA pre-submission process for their kitted clinical test is underway, with a meeting scheduled for December. The company recently raised $10.2 million through a private placement at market price of $2.948 per share.
Oncocyte Corp (Nasdaq: OCX) has announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day. Investors can access the call via toll-free number 800-715-9871 for domestic callers or +1 (646) 307-1963 for international callers, using Conference ID 4153469. A webcast replay will be available on the company's website after the call.
Oncocyte Corp (NASDAQ: OCX), a diagnostics technology company, announced its participation in the 17th annual LD Micro Main Event in Los Angeles. CEO Josh Riggs is scheduled to present on Tuesday, October 29th at 2:30 PM PT at The Luxe Sunset Boulevard Hotel. The company's management will also be available for one-on-one meetings with investors.
The LD Micro Main Event XVII will run from October 28th to 30th, featuring approximately 150 companies presenting in half-hour increments and attending private meetings with investors. Registration begins on October 28th at 3:00 PM PT, followed by keynotes and a happy hour. Presentations will run from 8:00 AM to 5:00 PM PT on October 29th and 30th.
Oncocyte Corp. (Nasdaq: OCX) has announced positive data for its DetermaIO™ gene expression test in a peer-reviewed publication. The NeoTRIP Phase 2 clinical trial assessed DetermaIO's ability to predict which triple-negative breast cancer (TNBC) patients would benefit from adding atezolizumab (immunotherapy) to chemotherapy.
Key findings include:
- DetermaIO-positive patients showed a significantly higher pathologic complete response (pCR) rate with atezolizumab plus chemotherapy (69.8%) compared to chemotherapy alone (46.9%).
- DetermaIO was the only biomarker among those tested that significantly predicted pCR benefit from adding atezolizumab.
- Results were further validated using data from the I-SPY2 Trial with pembrolizumab.
Oncocyte aims to commercialize DetermaIO within 18 months, targeting a multi-billion-dollar oncology diagnostics market.
Oncocyte (Nasdaq: OCX) has announced new agreements with two leading transplant university hospitals in the U.S. and Germany to utilize GraftAssure™, the company's research-use-only assay for detecting early evidence of graft organ damage. This development is part of Oncocyte's strategy to drive commercial adoption of its molecular diagnostic tests in the estimated $1 billion transplant addressable market.
The company has also submitted its plan for an in-vitro diagnostic (IVD) version of its dd-cfDNA kitted test to the FDA, initiating the Q-submission process. A meeting with the FDA is scheduled for early December. Oncocyte aims to begin the validation process in early 2025.
Since August 2024, additional transplant centers have committed to adopting GraftAssure. Oncocyte partnered with Bio-Rad Laboratories in April 2024 for global launch support, with Bio-Rad having exclusive distribution rights outside the U.S. and Germany.
Oncocyte (Nasdaq: OCX) has announced a $10.2 million private placement of securities priced at-the-market under Nasdaq rules. The company has secured participation from new and existing investors, including strategic partner Bio-Rad Laboratories. The private placement involves the sale of 3,461,138 shares of common stock at $2.948 per share, with certain insiders subscribing for 37,037 shares at $2.970 per share.
The net proceeds will be used for working capital and general corporate purposes. The placement is expected to close on or about October 4, 2024, subject to customary closing conditions. Oncocyte's CEO, Josh Riggs, stated that this funding will help expand access to organ transplant rejection testing globally. The company has also entered into a registration rights agreement to file a registration statement with the SEC within 15 days.
Oncocyte Corp. (Nasdaq: OCX) announced the publication of a case series study using its VitaGraft™ Kidney diagnostic test to monitor antibody-mediated rejection (AMR) in kidney transplant patients treated with daratumumab. The study showcases the test's potential to monitor anti-CD38 therapy efficacy. VitaGraft Kidney, a noninvasive biomarker, measures donor kidney DNA in patient blood post-transplantation.
Key findings include:
- Two patients with biopsy-confirmed chronic active AMR showed stabilized kidney function and decreased dd-cfDNA levels after daratumumab treatment
- Biopsies revealed complete or partial resolution of AMR activity
- This is the second study demonstrating VitaGraft Kidney's ability to monitor therapeutic efficacy
Oncocyte aims to improve graft longevity by enabling AMR detection, management, and monitoring. The company is commercializing its transplant product line, including VitaGraft™ and GraftAssure™ tests.
Oncocyte (Nasdaq: OCX) has successfully launched GraftAssure™, a research-use-only assay detecting graft organ damage in blood. The assay debuted in July 2024 at major transplant centers in the U.S. and Asia. The company reported Q2 2024 revenue of $104,000, a $4.5 million loss from continuing operations, and an $11 million cash balance. The GraftAssure launch is part of a strategy to capture market share in a $1 billion market, aligning with Bio-Rad's global infrastructure. Positive momentum is reported from partnerships and industry relationships. Oncocyte aims to establish over 20 transplant centers running GraftAssure by the end of 2025, targeting significant future revenue. The company is also preparing for FDA IVD clearance in late 2025. Andrea James has been appointed CFO. Additional details are in the company's updated investor deck.
Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, has announced its participation in two investor conferences this August. CEO Josh Riggs and CFO Andrea James will represent the company at:
1. The 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 12-13, 2024, where they plan to host meetings with investors.
2. The Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. Oncocyte is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, and will also participate in one-on-one meetings.
Investors interested in scheduling meetings with Oncocyte's management team can contact their Needham or Sidoti representative or reach out to the company's IR contact directly.
Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. market close. The company will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss its financial results and highlights.
Interested parties can access the live call via telephone by dialing toll-free 800-715-9871 for domestic callers. The live webcast can be accessed through the 'Events & Presentations' section of Oncocyte's website. A replay of the webcast will be available on the company's website shortly after the call concludes.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What is the core focus of Oncocyte Corporation?
How do Oncocyte’s diagnostic tests work?
Which medical conditions does Oncocyte target?
What makes Oncocyte’s approach unique in the diagnostics industry?
Who are some of Oncocyte’s strategic partners?
How do liquid biopsy diagnostics benefit patient care?
What technologies underpin Oncocyte’s diagnostic assays?
How does Oncocyte differentiate itself from competitors?
